CLINICAL_TRIALS ClinicalTrials.gov record update

Combination of Pioglitazone and Tyrosine Kinase Inhibitor (TKI) in Relapsed Chronic Myeloid Leukemia Following a First TKI Discontinuation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02730195
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:03.229354+00:00
Published At: 2019-01-09T00:00:00+00:00
Record Updated At: 2019-01-09
Results Posted At: 2019-01-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-01-09"
protocolSection.identificationModule.nctId: "NCT02730195"
protocolSection.identificationModule.officialTitle: "Combination of Pioglitazone and Tyrosine Kinase Inhibitor (TKI) in Relapsed Chronic Myeloid Leukemia Following a First TKI Discontinuation"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-01-09"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.